DOCSLIB.ORG

Poisons Standard June 2021

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Poisons Standard June 2021 Poisons Standard June 2021 I, Avi Rebera, as delegate of the Secretary of the Department of Health, make the following Poisons Standard. Dated 26 May 2021 Avi Rebera Assistant Secretary Regulatory Engagement, Education and Planning Branch Health Products Regulation Group Department of Health Poisons Standard June 2021 i Authorised Version F2021L00650 registered 26/05/2021 1 Name This instrument is the Poisons Standard June 2021. 2 Commencement (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms. Commencement information Column 1 Column 2 Column 3 Provisions Commencement Date/Details 1. The whole of this 1 June 2021. 1 June 2021 instrument Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument. (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument. 3 Authority This instrument is made under paragraph 52D(2)(b) of the Therapeutic Goods Act 1989. 4 Current Poisons Standard Schedule 1 to this instrument contains the Standard for the Uniform Scheduling of Medicines and Poisons No. 33, otherwise known as the current Poisons Standard. 5 Repeals Each instrument that is specified in Schedule 2 to this instrument is repealed as set out in the applicable items in that Schedule. Poisons Standard June 2021 ii Authorised Version F2021L00650 registered 26/05/2021 Schedule 1—Standard for the Uniform Scheduling of Medicines and Poisons No. 33 Poisons Standard June 2021 iii Authorised Version F2021L00650 registered 26/05/2021 STANDARD FOR THE UNIFORM SCHEDULING OF MEDICINES AND POISONS No. 33 June 2021 Poisons Standard June 2021 iv Authorised Version F2021L00650 registered 26/05/2021 Reasons for scheduling delegates’ final decisions can be accessed from the TGA website, at https://www.tga.gov.au/reasons-scheduling-delegates-final-decisions Further inquiries in relation to this document should be directed to: The Secretary Chemicals and Medicines Scheduling Secretariat (MD122) Scheduling and Committee Governance Therapeutic Goods Administration PO Box 100 WODEN ACT 2606 or by email to [email protected] [email protected] Media Liaison Unit Australian Government Department of Health Poisons Standard June 2021 v Authorised Version F2021L00650 registered 26/05/2021 Table of Contents Table of Contents vi INTRODUCTION viii PART 1 1 INTERPRETATION ______________________________________________ 1 PART 2 11 CONTROL ON MEDICINES AND POISONS _______________________ 11 SECTION ONE LABELS __________________________________________ 11 SECTION TWO CONTAINERS _____________________________________ 22 SECTION THREE STORAGE ______________________________________ 28 SECTION FOUR DISPOSAL _________________________________________ 29 SECTION FIVE RECORD KEEPING ________________________________ 29 SECTION SIX SALE, SUPPLY, POSSESSION, or USE __________________ 29 SECTION SEVEN/Appendix I PAINT OR TINTERS ____________________ 30 PART 3 33 MISCELLANEOUS REGULATIONS ______________________________ 33 SECTION ONE ADVERTISING ____________________________________ 33 SECTION TWO SALE OR SUPPLY _________________________________ 33 SECTION THREE STORAGE ______________________________________ 34 PART 4 35 THE SCHEDULES ______________________________________________ 35 SCHEDULE 1 _____________________________________________________ 35 SCHEDULE 2 _____________________________________________________ 35 SCHEDULE 3 _____________________________________________________ 54 SCHEDULE 4 _____________________________________________________ 62 SCHEDULE 5 ____________________________________________________ 157 SCHEDULE 6 ____________________________________________________ 191 Poisons Standard June 2021 vi Authorised Version F2021L00650 registered 26/05/2021 SCHEDULE 7 ____________________________________________________ 246 SCHEDULE 8 ____________________________________________________ 259 SCHEDULE 9 ____________________________________________________ 263 SCHEDULE 10 ___________________________________________________ 271 PART 5 277 THE APPENDICES _____________________________________________ 277 APPENDIX A – GENERAL EXEMPTIONS ____________________________ 277 APPENDIX B – SUBSTANCES CONSIDERED NOT TO REQUIRE CONTROL BY SCHEDULING ________________________________________________ 280 APPENDIX C (see SCHEDULE 10) __________________________________ 299 APPENDIX D – ADDITIONAL CONTROLS ON POSSESSION OR SUPPLY OF POISONS INCLUDED IN SCHEDULE 4 OR 8 _________________________ 300 APPENDIX E – FIRST AID INSTRUCTIONS FOR POISONS _____________ 307 APPENDIX F – WARNING STATEMENTS AND GENERAL SAFETY DIRECTIONS FOR POISONS _______________________________________ 334 APPENDIX G – DILUTE PREPARATIONS ____________________________ 373 APPENDIX H – SCHEDULE 3 POISONS PERMITTED TO BE ADVERTISED376 APPENDIX I _____________________________________________________ 379 APPENDIX J – SCHEDULE 7 POISONS REQUIRING ADDITIONAL CONTROLS ON AVAILABILITY AND USE __________________________ 380 APPENDIX K – DRUGS REQUIRED TO BE LABELLED WITH A SEDATION WARNING ______________________________________________________ 386 APPENDIX L – REQUIREMENTS FOR DISPENSING LABELS FOR HUMAN AND VETERINARY MEDICINES ___________________________________ 396 APPENDIX M – ADDITIONAL CONTROLS OR SUPPLY REQUIREMENTS FOR POISONS INCLUDED IN SCHEDULE 3 TO ALLOW THEM TO BE PROVIDED BY A PHARMACIST ___________________________________ 400 INDEX 401 Poisons Standard June 2021 vii Authorised Version F2021L00650 registered 26/05/2021 INTRODUCTION The Poisons Standard June 2021, which, under section 4 above contains the Standard for the Uniform Scheduling of Medicines and Poisons No. 33 (“the Standard” or “the SUSMP”), is made under paragraph 52D(2)(b) of the Therapeutic Goods Act 1989, and is a compilation of decisions made under section 52D of the same Act. The SUSMP should be read in conjunction with the Scheduling Policy Framework (“SPF”) of the Australian Health Ministers' Advisory Council. Further information on the scheduling amendments and the SPF can be accessed at www.tga.gov.au. Refer to Part 1, Interpretation, on page 2 below for definitions of specific terms used in this document including “medicine” and “poison” (noting that the definition of poison includes medicine). The SUSMP serves two key purposes. Firstly, the SUSMP contains the decisions of the Secretary of the Department of Health or the Secretary's delegates regarding the classification of poisons into Schedules, as recommendations to Australian States and Territories. The scheduling classification sets the level of control on the availability of poisons. The scheduling of poisons is implemented through relevant State and Territory legislation. Certain advertising, labelling and packaging requirements may also be a consequence of scheduling, but are the subject of other Commonwealth registration schemes. Secondly, the SUSMP includes provisions for labelling, containers, storage, disposal, record- keeping, sale, supply and possession of poisons in general which are intended to be adopted for use in each jurisdiction of Australia. Other government agencies may also impose controls on certain products. The requirements for labelling and containers in the SUSMP are intended to integrate with existing legislative instruments for labelling and containers. Advertising, labelling and packaging of therapeutic goods and agricultural and veterinary chemicals are also dealt with through the respective product registration schemes provided for in Commonwealth legislation. Poisons which are packed and sold solely for industrial, manufacturing, laboratory or dispensary use are exempt from all labelling requirements included in the SUSMP as they are covered by labelling requirements under applicable jurisdictional Work Health and Safety laws, as amended from time to time. Note, however that this exemption does not extend to controls on supply of these poisons. The SUSMP is presented with a view to promoting uniform: scheduling of poisons throughout Australia; signal headings on labels for poisons throughout Australia; labelling and packaging requirements for poisons throughout Australia; additional controls on the availability and use of poisons in Australia. The various Commonwealth Acts, legislative instruments and other documents, which integrate with the SUSMP include: the Agricultural and Veterinary Chemicals Code Act 1994; the Agricultural and Veterinary Chemicals Code Regulations 1995; Poisons Standard June 2021 viii Authorised Version F2021L00650 registered 26/05/2021 the Therapeutic Goods Act 1989; the Therapeutic Goods Order No. 91 – Standard for labels of prescription and related medicines (Compilation No. 2); the Therapeutic Goods Order No. 92 – Standard for labels of non-prescription medicines (Compilation No. 1); the Therapeutic Goods Order No. 95 – Child-resistant packaging requirements for medicines 2017 (TGO 95); the Therapeutic Goods (Medicines Advisory Statements) Specification 2019 – Schedule 1 Required Advisory Statements for Medicine Labels (RASML). CLASSIFICATION Poisons are classified according to the Schedules in which they are included. The following is a general description of the Schedules. For
Load more

Recommended publications
  • NCAA [R] Drug-Testing Program, 1999-2000
    DOCUMENT RESUME ED 436 990 HE 032 608 AUTHOR Halpin, Ty, Ed. TITLE NCAA[R] Drug-Testing Program, 1999-2000. INSTITUTION National Collegiate Athletic Association, Indianapolis, IN. PUB DATE 1999-00-00 NOTE 15p. AVAILABLE FROM National Collegiate Athletic Association, P.O. Box 6222, Indianapolis, IN 46206-6222. Tel: 317-917-6222. PUB TYPE Legal/Legislative/Regulatory Materials (090) EDRS PRICE MF01/PC01 Plus Postage. DESCRIPTORS Athletes; *College Athletics; Drug Abuse; *Drug Use Testing; Higher Education; Illegal Drug Use IDENTIFIERS *National Collegiate Athletic Association ABSTRACT The drug testing program supports NCAA's goal to protect the health and safety of student-athletes competing for their institutions, while reaffirming the organization's commitment to fair and equitable competition. Proposal Nos. 30 and 52-54 provide a program for the NCAA's members to ensure that no one athlete has a chemically-induced advantage or is pressured to use chemical substances. The program involves urine collection on specific occasions and laboratory analyses for substances on a list of banned drugs including stimulants, anabolic agents such as steroids, diuretics, illegal drugs, or peptide hormones. Consent forms must be signed by student athletes if they wish to participate in NCAA programs. (JM) Reproductions supplied by EDRS are the best that can be made from the original document. 6' 3r; - RUG- ESTING ROGRAI4 1999-2000 , Pso (2 BEST COPY AVAILABLE U.S. DEPARTMENT OF EDUCATION Office of Educational Research and Improvement PERMISSION TO REPRODUCE AND EDUCATIONAL RESOURCES INFORMATION DISSEMINATE THIS MATERIAL HAS CENTER (ERIC) BEEN GRANTED BY his document has been reproduced as received from the person or organization originating it.
    [Show full text]
  • LGM-Pharma-Regulatory-1527671011
    Pipeline Products List Specialty Portfolio Updated Q2 2018 Updated Q2 2018 See below list of newly approved API’s, samples are readily available for your R&D requirements: Inhalation Ophthalmic Transdermal Sublingual Abaloparatide Defibrotide Sodium Liraglutide Rituximab Abciximab Deforolimus Lixisenatide Rivastigmine Aclidinium Bromide Azelastine HCl Agomelatine Alprazolam Abemaciclib Delafloxacin Lumacaftor Rivastigmine Hydrogen Tartrate Beclomethasone Dipropionate Azithromycin Amlodipine Aripiprazole Acalabrutinib Denosumab Matuzumab Rizatriptan Benzoate Budesonide Besifloxacin HCl Apomorphine Eletriptan HBr Aclidinium Bromide Desmopressin Acetate Meloxicam Rocuronium Bromide Adalimumab Difluprednate Memantine Hydrochloride Rolapitant Flunisolide Bimatoprost Clonidine Epinephrine Aflibercept Dinoprost Tromethamine Micafungin Romidepsin Fluticasone Furoate Brimonidine Tartrate Dextromethorphan Ergotamine Tartrate Agomelatine Dolasetron Mesylate Mitomycin C Romosozumab Fluticasone Propionate Bromfenac Sodium Diclofenac Levocetrizine DiHCl Albiglutide Donepezil Hydrochloride Mometasone Furoate Rotigotine Formoterol Fumarate Cyclosporine Donepezil Meclizine Alectinib Dorzolamide Hydrochloride Montelukast Sodium Rucaparib Iloprost Dexamethasone Valerate Estradiol Melatonin Alemtuzumab Doxercalciferol Moxifloxacin Hydrochloride Sacubitril Alirocumab Doxorubicin Hydrochloride Mycophenolate Mofetil Salmeterol Xinafoate Indacaterol Maleate Difluprednate Fingolimod Meloxicam Amphotericin B Dulaglutide Naldemedine Secukinumab Levalbuterol Dorzolamide
    [Show full text]
  • (12) United States Patent (10) Patent N0.: US 8,343,962 B2 Kisak Et Al
    US008343962B2 (12) United States Patent (10) Patent N0.: US 8,343,962 B2 Kisak et al. (45) Date of Patent: *Jan. 1, 2013 (54) TOPICAL FORMULATION (58) Field of Classi?cation Search ............. .. 514/226.5, 514/334, 420, 557, 567 (75) Inventors: Edward T. Kisak, San Diego, CA (US); See application ?le fOr Complete Search history. John M. NeWsam, La Jolla, CA (US); _ Dominic King-Smith, San Diego, CA (56) References C‘ted (US); Pankaj Karande, Troy, NY (US); Samir Mitragotri, Goleta, CA (US) US' PATENT DOCUMENTS 5,602,183 A 2/1997 Martin et al. (73) Assignee: NuvoResearchOntano (CA) Inc., Mississagua, 6,328,979 2B1 12/2001 Yamashita et a1. 7,001,592 B1 2/2006 Traynor et a1. ( * ) Notice: Subject to any disclaimer, the term of this 7,795,309 B2 9/2010 Kisak eta1~ patent is extended or adjusted under 35 2002/0064524 A1 5/2002 Cevc U.S.C. 154(b) by 212 days. FOREIGN PATENT DOCUMENTS This patent is subject to a terminal dis- W0 WO 2005/009510 2/2005 claimer- OTHER PUBLICATIONS (21) APPI' NO‘, 12/848,792 International Search Report issued on Aug. 8, 2008 in application No. PCT/lB2007/0l983 (corresponding to US 7,795,309). _ Notice ofAlloWance issued on Apr. 29, 2010 by the Examiner in US. (22) Med Aug- 2’ 2010 Appl. No. 12/281,561 (US 7,795,309). _ _ _ Of?ce Action issued on Dec. 30, 2009 by the Examiner in US. Appl. (65) Prior Publication Data No, 12/281,561 (Us 7,795,309), Us 2011/0028460 A1 Feb‘ 3’ 2011 Primary Examiner * Raymond Henley, 111 Related U 5 Application Data (74) Attorney, Agent, or Firm * Foley & Lardner LLP (63) Continuation-in-part of application No.
    [Show full text]
  • Therapeutic Potential for Coxibs-Nitric Oxide Releasing Hybrids in Cystic fibrosis
    European Journal of Medicinal Chemistry xxx (xxxx) xxx Contents lists available at ScienceDirect European Journal of Medicinal Chemistry journal homepage: http://www.elsevier.com/locate/ejmech Research paper Therapeutic potential for coxibs-nitric oxide releasing hybrids in cystic fibrosis Sara Consalvi a, Giovanna Poce a, Carla Ghelardini b, Lorenzo Di Cesare Mannelli b, Paola Patrignani c, Annalisa Bruno c, Maurizio Anzini d, Vincenzo Calderone e, * Alma Martelli e, Lara Testai e, Antonio Giordani f, Mariangela Biava a, a Department of Chemistry and Technologies of Drug, Sapienza University of Rome, Piazzale A. Moro 5, 00185, Rome, Italy b Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Via Schiff 6, Sesto Fiorentino, 50019, Florence, Italy c Department of Neuroscience, Imaging and Clinical Sciences, And Center for Advanced Studies and Technology (CAST), School of Medicine, G. D’Annunzio University, Chieti, Italy d Department of Biotechnology, Chemistry, And Pharmacy, DoE 2018-2022, University of Siena, 53100, Siena, Italy e Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126, Pisa, Italy f Formerly Rottapharm at the Present Consultant, Italy article info abstract Article history: This review discusses the rational for further studies of COX-2 inhibitors-NO releaser hybrids (NO- Received 4 June 2020 Coxibs) in the pharmacological treatment of the airway inflammation in Cystic Fibrosis (CF). Our research Received in revised form group developed several classes of NO-Coxibs for the pharmacological treatment of arthritis, and among 27 October 2020 them several compounds showed an outstanding in vivo efficacy and good pharmacokinetic properties. Accepted 28 October 2020 The good antiinflammatory properties displayed by these compounds during the previous screening could, by itself, suggest appropriate candidates for further testing in CF.
    [Show full text]
  • Properties and Units in Clinical Pharmacology and Toxicology
    Pure Appl. Chem., Vol. 72, No. 3, pp. 479–552, 2000. © 2000 IUPAC INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE SCIENTIFIC DIVISION COMMITTEE ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)# and INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY CHEMISTRY AND HUMAN HEALTH DIVISION CLINICAL CHEMISTRY SECTION COMMISSION ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)§ PROPERTIES AND UNITS IN THE CLINICAL LABORATORY SCIENCES PART XII. PROPERTIES AND UNITS IN CLINICAL PHARMACOLOGY AND TOXICOLOGY (Technical Report) (IFCC–IUPAC 1999) Prepared for publication by HENRIK OLESEN1, DAVID COWAN2, RAFAEL DE LA TORRE3 , IVAN BRUUNSHUUS1, MORTEN ROHDE1, and DESMOND KENNY4 1Office of Laboratory Informatics, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark; 2Drug Control Centre, London University, King’s College, London, UK; 3IMIM, Dr. Aiguader 80, Barcelona, Spain; 4Dept. of Clinical Biochemistry, Our Lady’s Hospital for Sick Children, Crumlin, Dublin 12, Ireland #§The combined Memberships of the Committee and the Commission (C-NPU) during the preparation of this report (1994–1996) were as follows: Chairman: H. Olesen (Denmark, 1989–1995); D. Kenny (Ireland, 1996); Members: X. Fuentes-Arderiu (Spain, 1991–1997); J. G. Hill (Canada, 1987–1997); D. Kenny (Ireland, 1994–1997); H. Olesen (Denmark, 1985–1995); P. L. Storring (UK, 1989–1995); P. Soares de Araujo (Brazil, 1994–1997); R. Dybkær (Denmark, 1996–1997); C. McDonald (USA, 1996–1997). Please forward comments to: H. Olesen, Office of Laboratory Informatics 76-6-1, Copenhagen University Hospital (Rigshospitalet), 9 Blegdamsvej, DK-2100 Copenhagen, Denmark. E-mail: [email protected] Republication or reproduction of this report or its storage and/or dissemination by electronic means is permitted without the need for formal IUPAC permission on condition that an acknowledgment, with full reference to the source, along with use of the copyright symbol ©, the name IUPAC, and the year of publication, are prominently visible.
    [Show full text]
  • Supplementary Information
    Supplementary Information Network-based Drug Repurposing for Novel Coronavirus 2019-nCoV Yadi Zhou1,#, Yuan Hou1,#, Jiayu Shen1, Yin Huang1, William Martin1, Feixiong Cheng1-3,* 1Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA 2Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA 3Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA #Equal contribution *Correspondence to: Feixiong Cheng, PhD Lerner Research Institute Cleveland Clinic Tel: +1-216-444-7654; Fax: +1-216-636-0009 Email: [email protected] Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. Supplementary Table S2. Protein sequence identities across 5 protein regions in 15 coronaviruses. Supplementary Table S3. HCoV-associated host proteins with references. Supplementary Table S4. Repurposable drugs predicted by network-based approaches. Supplementary Table S5. Network proximity results for 2,938 drugs against pan-human coronavirus (CoV) and individual CoVs. Supplementary Table S6. Network-predicted drug combinations for all the drug pairs from the top 16 high-confidence repurposable drugs. 1 Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. GenBank ID Coronavirus Identity % Host Location discovered MN908947 2019-nCoV[Wuhan-Hu-1] 100 Human China MN938384 2019-nCoV[HKU-SZ-002a] 99.99 Human China MN975262
    [Show full text]
  • Amyl Nitrite Or 'Jungle Juice'
    Young People and Other Drugs Amyl Nitrite or ‘Jungle Juice’ Amyl nitrite is an inhalant that belongs to a class As with any drug, the use of nitrites is not risk-free. of chemicals called alkyl nitrites. This group of Some of the harms associated with its use include: drugs can be called ‘poppers’. They are often injuries related to inhaling the vapour referred to by their brand name, with ‘Jungle (e.g., rashes, burns) Juice’ probably being the most well-known of these. allergic reactions accidents and falls Inhaling amyl nitrite relaxes the body and gives vision problems (isopropyl nitrite) a ‘rush’ that lasts for one to two minutes. It is commonly used to enhance sexual pleasure and in rare cases, blood disorders induce a feeling of euphoria and well-being. MOST IMPORTANTLY, AMYL NITRITE OR JUNGLE JUICE MUST NEVER BE DRUNK. Drinking amyl can result in death due to it interfering with the ability of the blood to transport oxygen. What is amyl nitrite? Over the years, to bypass legal restrictions, nitrites have been sold as such things as liquid incense or Amyl nitrite is an inhalant that belongs to a class of room odoriser. Jungle Juice, which can be sold as chemicals called alkyl nitrites. Amyl nitrite is a highly a leather cleaner, is a common product name of flammable liquid that is clear or yellowish in colour. amyl nitrite. It has a unique smell that is sometimes described as ‘dirty socks’. It is highly volatile and when exposed to the air evaporates almost immediately at How is Jungle Juice used? room temperature.
    [Show full text]
  • Notice of Final Decisions to Amend (Or Not Amend) the Current Poisons Standard
    Notice of final decisions to amend (or not amend) the current Poisons Standard Final decisions and reasons for New Chemical Entities and medicines and chemicals referred to the November 2018 scheduling meetings 26 April 2019 Scheduling amendments referred to expert advisory committee Subdivision 3D.2 of the Therapeutic Goods Regulations 1990 (the Regulations) sets out the procedure to be followed where the Secretary receives an application under section 52EAA of the Therapeutic Goods Act 1989 (the Act) to amend the current Poisons Standard and decides to refer the proposed amendment to an expert advisory committee. These include, under regulation 42ZCZK, that the Secretary publish (in a manner the Secretary considers appropriate) the proposed amendment to be referred to an expert advisory committee, the committee to which the proposed amendment will be referred, and the date of the committee meeting. The Secretary must also invite public submissions to be made to the expert advisory committee by a date mentioned in the notice as the closing date, allowing at least 20 business days after publication of the notice. Such a notice relating to the final decisions herein was made available on the TGA website at Scheduling advisory committees: invitations for public comment on 31 August 2018 and closed on 28 September 2018. Public submissions received on or before this closing date were published on the TGA website at Public submissions on scheduling matters referred to the ACMS #25, ACCS #23 and Joint ACMS-ACCS #20 meetings held in November 2018, in accordance with regulation 42ZCZL. Under regulation 42ZCZN of the Regulations, the Secretary, after considering the advice or recommendation of the expert advisory committee, must (subject to regulation 42ZCZO) make an interim decision in relation to the proposed amendment.
    [Show full text]
  • Primary-Explosives
    Improvised Primary Explosives © 1998 Dirk Goldmann No part of the added copyrighted parts (except brief passages that a reviewer may quote in a review) may be reproduced in any form unless the reproduced material includes the following two sentences: The copyrighted material may be reproduced without obtaining permission from anyone, provided: (1) all copyrighted material is reproduced full-scale. WARNING! Explosives are danegerous. In most countries it's forbidden to make them. Use your mind. You as an explosives expert should know that. 2 CONTENTS Primary Explosives ACETONE PEROXIDE 4 DDNP/DINOL 6 DOUBLE SALTS 7 HMTD 9 LEAD AZIDE 11 LEAD PICRATE 13 MEKAP 14 MERCURY FULMINATE 15 "MILK BOOSTER" 16 NITROMANNITE 17 SODIUM AZIDE 19 TACC 20 Exotic and Friction Primers LEAD NITROANILATE 22 NITROGEN SULFIDE 24 NITROSOGUANIDINE 25 TETRACENE 27 CHLORATE-FRICTION PRIMERS 28 CHLORATE-TRIMERCURY-ACETYLIDE 29 TRIHYDRAZINE-ZINC (II) NITRATE 29 Fun and Touch Explosives CHLORATE IMPACT EXPLOSIVES 31 COPPER ACETYLIDE 32 DIAMMINESILVER II CHLORATE 33 FULMINATING COPPER 33 FULMINATING GOLD 34 FULMINATING MERCURY 35 FULMINATING SILVER 35 NITROGEN TRICHLORIDE 36 NITROGEN TRIIODIDE 37 SILVER ACETYLIDE 38 SILVER FULMINATE 38 "YELLOW POWDER" 40 Latest Additions 41 End 3 PRIMARY EXPLOSIVES ACETONE PEROXIDE Synonyms: tricycloacetone peroxide, acetontriperoxide, peroxyacetone, acetone hydrogen explosive FORMULA: C9H18O6 VoD: 3570 m/s @ 0.92 g/cc. 5300 m/s @ 1.18 g/cc. EQUIVALENCE: 1 gram = No. 8 cap .75 g. = No. 6 cap SENSITIVITY: Very sensitive to friction, flame and shock; burns violently and can detonate even in small amounts when dry. DRAWBACKS: in 10 days at room temp. 50 % sublimates; it is best made immediately before use.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Computational Drug Target Screening Through Protein Interaction Profiles
    www.nature.com/scientificreports OPEN Computational Drug Target Screening through Protein Interaction Profiles Received: 27 June 2016 Santiago Vilar1,2, Elías Quezada3, Eugenio Uriarte2, Stefano Costanzi4, Fernanda Borges3, Accepted: 24 October 2016 Dolores Viña5 & George Hripcsak1 Published: 15 November 2016 The development of computational methods to discover novel drug-target interactions on a large scale is of great interest. We propose a new method for virtual screening based on protein interaction profile similarity to discover new targets for molecules, including existing drugs. We calculated Target Interaction Profile Fingerprints (TIPFs) based on ChEMBL database to evaluate drug similarity and generated new putative compound-target candidates from the non-intersecting targets in each pair of compounds. A set of drugs was further studied in monoamine oxidase B (MAO-B) and cyclooxygenase-1 (COX-1) enzyme through molecular docking and experimental assays. The drug ethoxzolamide and the natural compound piperlongumine, present in Piper longum L, showed hMAO-B activity with IC50 values of 25 and 65 μM respectively. Five candidates, including lapatinib, SB-202190, RO-316233, GW786460X and indirubin-3′-monoxime were tested against human COX-1. Compounds SB-202190 and RO-316233 showed a IC50 in hCOX-1 of 24 and 25 μM respectively (similar range as potent inhibitors such as diclofenac and indomethacin in the same experimental conditions). Lapatinib and indirubin- 3′-monoxime showed moderate hCOX-1 activity (19.5% and 28% of enzyme inhibition at 25 μM respectively). Our modeling constitutes a multi-target predictor for large scale virtual screening with potential in lead discovery, repositioning and drug safety. Discovery of new targets for molecules is of great interest in drug design and development1,2.
    [Show full text]
  • OREXIN ANTAGONISTS BELSOMRA (Suvorexant), DAYVIGO (Lemborexant)
    OREXIN ANTAGONISTS BELSOMRA (suvorexant), DAYVIGO (lemborexant) RATIONALE FOR INCLUSION IN PA PROGRAM Background Belsomra (suvorexant) and Dayvigo (lemborexant) are orexin receptor antagonists used to treat difficulty in falling and staying asleep (insomnia). Orexins are chemicals that are involved in regulating the sleep-wake cycle and play a role in keeping people awake (1-2). Regulatory Status FDA-approved indication: Orexin receptor antagonists are indicated for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance (1-2). Orexin Antagonists are contraindicated in patients with narcolepsy (1-2). Orexin Antagonists are central nervous system (CNS) depressants that can impair daytime wakefulness even when used as prescribed. Medications that treat insomnia can cause next-day drowsiness and impair driving and other activities that require alertness. Orexin Antagonists can impair driving skills and may increase the risk of falling asleep while driving. People can be impaired even when they feel fully awake. Patients should also be made aware of the potential for next-day driving impairment, because there is individual variation in sensitivity to the drug (1-2). The failure of insomnia to remit after 7 to 10 days of treatment may indicate the presence of a primary psychiatric and/or mental illness that should be evaluated (1-2). Warnings and precautions that should be discussed with the patient on Orexin Antagonist therapy include adverse reactions on abnormal thinking and behavioral changes (such as amnesia, anxiety, hallucinations and other neuropsychiatric symptoms), complex behaviors (such as sleep- driving, preparing and eating food, or making phone calls), dose-dependent increase in suicidal ideation, and sleep paralysis which is the inability to move or speak for up to several minutes during sleep-wake transitions (1-2).
    [Show full text]